New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2014
08:59 EDTVCYTVeracyte shares well positioned in 2014, says Leerink
Leerink believes Veracyte shares are well positioned in 2014 with potential catalysts from additional positive coverage decisions and the launch of the Afirma malignant test. The firm raised its price target for shares to $21 from $17 and maintains an Outperform rating on the name.
News For VCYT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 21, 2015
16:54 EDTVCYTVeracyte files to sell 4.9M shares of common stock for holders
Subscribe for More Information
May 20, 2015
15:32 EDTVCYTVeracyte reports positive data on company's molecular classifier
Subscribe for More Information
May 18, 2015
10:18 EDTVCYTVeracyte has Percepta market opportunity above $175M, says Piper Jaffray
Following the publication of results from studies that assessed the performance of Veracyte's Percepta test in lung cancer diagnosis, Piper Jaffray said the data was in line with previous diligence and that it expects the NEJM publication to help drive adoption. The firm, which estimates the initial domestic market opportunity for the test at $177M-$236M, kept its Overweight rating and $13 price target on Veracyte shares.
07:10 EDTVCYTVeracyte announces publication of results from two Percepta trials
Veracyte announced online publication in the New England Journal of Medicine of results from two large, prospective, multicenter studies that assessed the clinical performance of the company's Percepta Bronchial Genomic Classifier in lung cancer diagnosis. Findings from the AEGIS I and AEGIS II trials demonstrate the ability of the genomic test to help patients safely avoid unnecessary invasive, risky procedures on suspicious lung nodules or lesions that were initially found on computed tomography, or CT, scans. The AEGIS trials involved 639 patients at 28 sites in the United States, Canada and Ireland who were undergoing bronchoscopy, a common nonsurgical procedure, to assess lung nodules for cancer. Specifically, among patients assessed clinically as having "intermediate" risk of malignancy who then had a non-diagnostic bronchoscopy, the Percepta test had a negative predictive value, or NPV, of 91%, demonstrating the test's ability to reclassify these patients as "low risk" with a high degree of accuracy. The genomic test and the bronchoscopy had a combined sensitivity of 97%, compared to 75% for bronchoscopy alone. The genomic test's specificity was 47% in both studies. The sensitivity of the Percepta classifier alone and in combination with bronchoscopy was consistently high, regardless of nodule size and location, and cancer stage and type.
07:04 EDTVCYTVeracyte announces publication of results from two studies of Percepta
Subscribe for More Information
05:03 EDTVCYTVeracyte Percepta study published in New England Journal of Medicine
Veracyte announced online publication in the New England Journal of Medicine of results from two large, prospective, multicenter studies that assessed the clinical performance of the company's Percepta Bronchial Genomic Classifier in lung cancer diagnosis. Findings from the AEGIS I and AEGIS II trials demonstrate the ability of the genomic test to help patients safely avoid unnecessary invasive, risky procedures on suspicious lung nodules or lesions that were initially found on computed tomography, or CT, scans. The AEGIS trials involved 639 patients at 28 sites in the United States, Canada and Ireland who were undergoing bronchoscopy, a common nonsurgical procedure, to assess lung nodules for cancer. Specifically, among patients assessed clinically as having "intermediate" risk of malignancy who then had a non-diagnostic bronchoscopy, the Percepta test had a negative predictive value, or NPV, of 91%, demonstrating the test's ability to reclassify these patients as "low risk" with a high degree of accuracy. The genomic test and the bronchoscopy had a combined sensitivity of 97%, compared to 75% for bronchoscopy alone. The genomic test's specificity was 47% in both studies. The sensitivity of the Percepta classifier alone and in combination with bronchoscopy was consistently high, regardless of nodule size and location, and cancer stage and type.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use